Oncology Consortium

Impactful Education Through Innovative Engagement

roy.berger@theoncologyconsortium.com | (516) 729-0303

Ronald Bukowski, MD

Dermatologic and Urologic Oncology Consortium

Emeritus staff at the Cleveland Clinic Foundation, and Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. He was recently the Deputy Director of the Cleveland Clinic Taussig Cancer Center and Director of the Experimental Therapeutics at the Cleveland Clinic Cancer Center. He held the James Zito Chair in Cancer Research at the Taussig Cancer Center from 2001 to 2008.


Marc S. Ernstoff, MD

Dermatologic Oncology Consortium

Dr. Ernstoff is Professor of Medicine, Geisel School of Medicine; and Staff Physician at the Lerner School of Medicine at the Cleveland Clinic. He is currently the Geisel PI on the Cancer Immunotherapy Trial Network and is on the executive council of the Cytokine Working Group. Dr. Ernstoff is also a member of the Alliance Experimental Therapeutics Program.


John M. Kirkwood, MD

Dermatologic Oncology Consortium

Director of the Melanoma and Skin Cancer Program at the University of Pittsburgh Cancer Institute and Professor and Vice Chairman for Clinical Research at the University of Pittsburgh School of Medicine. Dr. Kirkwood has received international acclaim for his research in biologic agents, cancer vaccines, and molecular changes in melanoma.


Mario E. Lacouture, MD

Dermatologic Oncology Consortium

Dr Lacouture is a Board-certified dermatologist with special interest in dermatologic conditions in people living with cancer. His clinical career has been focused on the recognition and management of side effects affecting the skin, hair, and nails of cancer patients and survivors. His clinical program provides pretreatment counseling and preventive efforts to minimize the development of adverse events as well as rapid attention to people who develop them. Close communication with treating oncologists ensures that interventions against untoward events do not affect the effectiveness of cancer treatments. In summary, the ultimate goal is to ensure the best dermatology-related quality of life and benefit from anticancer treatments.

DOC_Cover_Page
Download Capability Slide

Oncology Consortium | All Rights Reserved 2012-2017
Back to Top